Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal antibody isatuximab to the VRd regimen would reduce the risk of disease progression or death among patients ineligible to undergo transplantation is unclear. METHODS: In an international, open-label, phase 3 trial, we randomly assigned, in a 3:2 ratio, patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation to receive either isatuximab plus VRd or VRd alone. The primary efficacy end point was progression-free survival. Key secondary end points included a complete response or better and minimal residual disease (MRD)-negative status in patients with a complete response. RESULTS: A total of 446 patients underwent randomization. At a median follow-up of 59.7 months, the estimated progression-free survival at 60 months was 63.2% in the isatuximab-VRd group, as compared with 45.2% in the VRd group (hazard ratio for disease progression or death, 0.60; 98.5% confidence interval, 0.41 to 0.88; P<0.001). The percentage of patients with a complete response or better was significantly higher in the isatuximab-VRd group than in the VRd group (74.7% vs. 64.1%, P = 0.01), as was the percentage of patients with MRD-negative status and a complete response (55.5% vs. 40.9%, P = 0.003). No new safety signals were observed with the isatuximab-VRd regimen. The incidence of serious adverse events during treatment and the incidence of adverse events leading to discontinuation were similar in the two groups. CONCLUSIONS: Isatuximab-VRd was more effective than VRd as initial therapy in patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation. (Funded by Sanofi and a Cancer Center Support Grant; IMROZ ClinicalTrials.gov number, NCT03319667.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Isatuximab plus VRd (Isa-VRd) has also shown impressive results in newly diagnosed myeloma.102,103”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [102]
Citations
Cites
1 retracted
Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia · doi:10.1038/leu.2015.240 · Cited by 219
RetractedKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationDaratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Self-citationDaratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Self-citationMoreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Self-citationDurie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Self-citationDaratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312054 · Cited by 599
Self-citation
Cited by
Items 201–283 of 283
Puertas, B., Alejo, E., Pérez, J. J., Serra-Toral, F., Padilla, I., Dávila, J., García‐Mateo, A., Alonso, J. M., Hernández, R. S., Aguilar-Franco, C., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.11.007
Jungová, A., Štork, M., Špıčka, I., Radocha, J., Minařík, J., Pavlíček, P., Mihályová, J., Pour, L., Štraub, J., Maisnar, V., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.022
Self-citationAktuelle Fortschritte und neue Therapieoptionen in der Immunonkologie
Kobold, S., & Müller, R. (2025) · TumorDiagnostik & Therapie · doi:10.1055/a-2736-7079
Aliyeva, T., Alamy, H., Ahmad, F. A. I., Natche, J., Shah, H., Shelar, V., Huynh, H. T., & Amri, I. E. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103559 · Cited by 1
Tan, M. S. Y., Nagarajan, C., Ooi, M. G. M., Mel, S. D., Hashim, N. S. B., Li, X., Chua, A., Pokharkar, Y. M., Tso, A. C. Y., Awasthi, N., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2602050
“Similarly, in IMROZ, bortezomib was administered twice weekly for 6 months—a schedule that may be difficult to tolerate in frailer patients typically underrepresented in clinical trials [8].”
Pichon, A., & Bobin, A. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.09.010
Wang, Y., Zhang, L., Dong, H., Chen, H., Zhang, H., Yuan, Y., Zhang, C., Feng, R., Wei, Y., & Wei, X. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100189 · Cited by 1
“…MRD-negativity and PFS in NDMM, including in patients with HRMM. 15 Similarly, isatuximab, another anti-CD38 mAb targeting a specific epitope of CD38, enhanced deep responses and PFS when combined with standard regimens in NDMM 27,28,30 ; however, the benefit in HRMM subpopulations was limited.”
Strotmann, A., Leitner, T., Mazzeo, P., Evers, G., Pohlmann, A., Eisfeld, C., Seib, M., von Bubnoff, N., Lenz, G., Shumilov, E., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.008
Klomberg, K. M., Gelderloos, M., Kooistra, H. A. M., Nijland, M., de Bock, G. H., Huls, G. A., Brink, M., Roeloffzen, W. W. H., & Plattel, W. J. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.007
Fortuna, G. G., Rahbari, K. J., Baljević, M., & Sborov, D. W. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.09.017
Hu, B., Fang, D. H., Jiang, L., Li, T., Chen, K., Cao, J., & Wang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1744165 · Cited by 1
Sim, S., McCaughan, G. J. B., Zannettino, A. C. W., Ho, P. J., Joshua, D., Talaulikar, D., Mollee, P. N., Prince, H. M., Spencer, A. G., Harrison, S. J., et al. (2026) · Internal Medicine Journal · doi:10.1111/imj.70329
Mohan, M., Radhakrishnan, S. V., Schinke, C., Katodritou, E., & Fonseca, R. (2026) · American Journal of Hematology · doi:10.1002/ajh.70215
“To the editor, A quadruple induction regimen based on an anti-CD38 monoclonal antibody (CD38 quads) is the current standard of care for all newly diagnosed multiple myeloma (MM) patients, except possibly for older, frail adults [1–4].”
A myeloma identity crisis yields daratumumab resistance
Pandey, A., & Diamond, B. T. (2026) · Blood · doi:10.1182/blood.2025031281
Landgren, O., Abonour, R., & Kazandjian, D. G. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.01.002 · Cited by 3
Sretenović, A., Mitrovic, M., Bukumirić, Z., Vukosavljevic, N., Kecman, N., Jovanović, J., Fekete, M. D., Zaric, E., & Bila, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1765235
First experience with Isatuximab in newly diagnosed multiple myeloma patients. Case report
Semenova, A., Zemlyakov, N., Kamyshanov, S. S., Cherentsova, A. I., Субботин, А. С., Tumyan, G. S., Baranova, O. Y., Строганова, А. М., & Arakelyan, A. V. (2026) · Journal of Modern Oncology · doi:10.26442/18151434.2025.4.203551
Hämatologische Neoplasien und solide Tumore
Ganser, A., Hertenstein, B., & Ludwig, W. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_5
Parrondo, R. D., de Menezes, R. C. B., Sledge, H. J., Nayyar, M., Yadav, K., Bergsagel, P. L., Fonseca, R., Kapoor, P., Buadi, F. K., Gertz, M. A., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70258
Cheng, L., Liang, D., Jia, J. L., Zhang, R., Yang, Y., Liu, P., Sun, H., Qin, X., Ma, Y., Wu, Y., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-15815-8
“As the clinical superiority was verified, quadruplet combination incorporating anti-CD38 antibody with VRd has been recommended as a front-line regimen for both trans-plant-eligible and ineligible NDMM patients [15].”
Louzada, M., Reece, D. E., Venner, C. P., White, D. J., Su, J., Chu, M. P., Zepeda, V. H. J., McCurdy, A. B. R., Song, K., Mian, H. S., et al. (2026) · Blood Neoplasia · doi:10.1016/j.bneo.2026.100215
Role of Radiotherapy in the Era of Novel Immune‐Based Treatment Strategies for Multiple Myeloma
Schlusemann, T., Shumilov, E., Reinartz, G., Steike, D. R., Lohmann, S., Gravemeyer, S., Stelljes, M., Lenz, G., Eich, H. T., & Oertel, M. (2026) · Hematological Oncology · doi:10.1002/hon.70186
Ocio, E. M., & Mateos, M. T. Á. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.004
Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection
Hadidi, S. A., Costello, C. L., Costa, L. J., Dhakal, B., Georges, P., Gajra, A., Lin, Y., Bhargava, R. S., Paner-Straseviciute, A., & Vij, R. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.009 · Cited by 1
Choosing an Initial Therapy Regimen for Newly Diagnosed Multiple Myeloma
Locke, M., Singhal, A., Ravichandran, M., & Nieto, M. J. (2025) · Journal of Clinical Haematology · doi:10.33696/haematology.6.069
Iriuchishima, H., Saito, A., Mihara, M., Kanaya, S., Yoshizawa, R., Isoda, A., & Matsumoto, M. (2026) · Cancers · doi:10.3390/cancers18071048
“In recent years, MM treatments have expanded with the arrival of quadruplet regimens [27,28], chimeric antigen receptor (CAR)-”
Yamauchi, N., Mishima, Y. M., Takayama, T., Minowa, S., Morita, Y., Momoki, M., Mima, F., Teramoto, Y., Koba, Y., Shirouchi, Y., et al. (2026) · Leukemia · doi:10.1038/s41375-026-02947-w
“Isatuximab, an anti-CD38 monoclonal antibody, has demonstrated cytotoxic effects through antibody-dependent cellular cytotoxicity (ADCC) in multiple myeloma (MM) [7, 8].”
Breaking new ground with antibody-drug conjugates in myeloma
Usmani, S. Z. (2026) · Blood · doi:10.1182/blood.2025032443
Lau, G., Chandra, M. B., Fero, H., & Alabbas, F. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04195-1 · Cited by 1
“The addition of anti-CD38 mAbs to alkylator-containing regimens (e.g. VMP, VCd) markedly deepened treatment responses, nearly quadrupling the rate of MRD negativity (RR 3.86, 95% CI: OCTANS [27, 28] AMaRC 03–16 [29] IMROZ [30] CEPHEUS [31, 32] GEM2017FIT†[33] First”
InfluentialNückel, H., Behlendorf, T., Schulz, H., Schulze, M. B., Schardt, C., Medinger, T., Koenigsmann, M., Dechow, T. N., Indorf, M., Bürkle, D., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.71758
Inoue, Y., Harada, T., Oda, A., Ohara, N., Nakagawa, H., Urushihara, M., Nakao, T., & Matsuoka, K.-I. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04210-5
“Recently, therapeutic regimens incorporating DARA or ISA during induction, consolidation, and maintenance phases have been developed and shown to achieve stringent complete remission and MRD negativity [18–20].”
Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Hoy, S. M. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01210-7
“Amongst the 446 enrolled patients, baseline demographic and disease characteristics were balanced across the isatuxi-mab–bortezomib–lenalidomide–dexamethasone and bortezomib–lenalidomide–dexamethasone groups ( n = 265 and 181) [26].”
InfluentialLiu, Y., Mo, C. C., Midha, S., Hartley-Brown, M. A., Lee, H. C., Franz, J. K., Nadeem, O., Nicholson, T., Salman, T. J., Fortune, A., et al. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2660911
“Isatuximab has been shown to exhibit strong antitumor effects in combination with IMiDs and PIs, as is evident from preclinical and clinical data [14,69,71,72].”
InfluentialIto, S., Namiki, T., Nukariya, H., Endo, T., Sugawasa, Y., Ichinohe, T., Kurihara, K., Hamada, T., Otake, S., Takahashi, H., et al. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04216-z
“Recently, the addition of isatuximab (Isa), a novel anti-CD38 monoclonal antibody, to conventional VRd (Isa-VRd) has demonstrated remarkable clinical outcomes in patients with NDMM who are ineligible for ASCT in the IMROZ study [3].”
Latif, K., Qi, J., Shah, P. D., & Akhtari, M. (2026) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096261446475
Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma
Fuentes-Lacouture, M. C., Nandana, D., Ramasamy, K., & Thakurta, A. (2026) · FEBS Journal · doi:10.1111/febs.70599
Clinical implications of minimal residual disease monitoring in multiple myeloma
Yoroidaka, T. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04229-8
“Sustained MRD negativity was also more frequently achieved in the IsaVRd group than in the VRd group (46.8% vs. 24.3%), and in both the IsaVRd and VRd groups, patients achieving sustained MRD negativity had the most favorable PFS outcomes [43].”
InfluentialHigh-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy
Morgan, G. J., Lee, D. D., Joseph, N. S., Lonial, S., Rodríguez‐Otero, P., & San-Miguel, J. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517494
Hansen, D. K., Mateos, M., & Costa, L. J. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019699
Zweegman, S., Facon, T. T. F., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M. J., Pour, L., Marti, J., Basu, S., Cohen, Y. C., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019937
“31 When applying a strict, IMWG definition of MRD negativity (10 –5 those in the VRd arm in CEPHEUS (39.4%); however, rates were numerically higher with D-VRd (60.9”
InfluentialSelf-citationMeasurable residual disease in myeloma: a MyRiaD of findings
Puig, N. (2026) · Blood · doi:10.1182/blood.2025032857
Bertuglia, G., Nicola, A. D., Gay, F., Larocca, A., Bruno, B., & D’Agostino, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1822419
“However, it is important to note that the trial comparator (DaraRd) may soon be outperformed by emerging quadruplet regimens, such as isatuximab – bortezomib – lenalidomide – dexamethasone (IsaVRd) and daratumumab-bortezomib-lenalidomide-dexamethasone (DaraVRd), in the NTE NDMM setting (18, 19).”
Theprungsirikul, P. P., Al-Musa, A., Bar, N., Browning, S. L., Parker, T., & Neparidze, N. (2026) · Cancers · doi:10.3390/cancers18121899
“The addition of isatuximab (ISA) to the VRD has been proven to improve the efficacy, PFS and depth of responses among transplant-ineligible patients with MM [22].”
Liang, T., Li, J., & Xu, C. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-00967-3
Improved survival in patients admitted to ICU with multiple myeloma: a retrospective cohort analysis
Nakaa, S., Caillot, L., Chermak, A., Kemp, H., Harel, S., Darmon, M., Azoulay, É., & Lemiale, V. (2026) · Annals of Intensive Care · doi:10.1016/j.aicoj.2026.100100
“…substantially improved due to the introduction of new agents, including proteasome inhibitors, immunomodulatory drugs, and CD38 monoclonal antibodies such as daratumumab, and more recently T cell engagers including bispecific antibodies and CAR-T cells, and risk-adapted treatment strategies [1].”
Ludwig, H., Terpos, E., Gay, F., van de Donk, N. W. C. J., Bernhard, S., Engelhardt, M. M., Cook, G., Schjesvold, F. H., Einsele, H., Jackson, G., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70397
“The IMROZ trial randomized 446 TI patients to either 4 cycles isatuximab- bortezomib- lenalidomide-dexamethasone (Isa-VRd) induction therapy followed by continued treatment with Isa-Rd or to the same regimens but without isatuximab [54].”
Self-citationLee, N., Kim, S., Lee, Y., Park, S. Y., Cho, H., Byun, J. M., Koh, Y., Hong, J., Shin, D.-Y., Min, C.-K., et al. (2026) · Blood Research · doi:10.1007/s44313-026-00149-y
“Nonetheless, as seen in the DETERMINATION trial and more recent clinical trials using quadruplet therapy, patients over 65 years of age are often considered “transplant-ineligi-ble” [8–10].”
Advancements in multiple myeloma treatment: Integrating quadruplet and dual antigen CAR-T therapy
Khan, M., Alfano, D., & Gupta, A. (2026) · iScience · doi:10.1016/j.isci.2026.116509
Mina, R., Terpos, E., Cani, L., Nooka, A. K., Trudel, S., Voorhees, P., Mian, H. S., Dhakal, B., Usmani, S. Z., Richter, J., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.06.014
Pathak, S., Ahmed, R., Nagy, N., Lee, S., Bader, C. S., Regmi, S., Iliopoulou, B. P., Chen, P.-I., Gupta, B., Villar‐Prados, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.27.734105
“The clinical efficacy of CD38 targeting antibodies has been primarily studied for the treatment of plasma cell dyscrasias, where the excessive production of non-functional autoantibodies can lead to direct organ toxicity and paraneoplastic autoimmune disorders 26,27 .”
de Ocáriz, X. G. L., Persona, E. P., Cuesta, L. S., Chacón, E. M., Sirvent, M., Austenrritt, P. M., Pérez, M. L., Landete, E., Baraja, V. C., Romero, I. S., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1906850
Mohyuddin, G. R., Alfaro, H. A. V., Godara, A., Goodman, A. M., Mainou, M., Chakraborty, R., Kugler, H. D., & Meirson, T. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104064
Solovev, M. V., Mendeleeva, L. P., Soloveva, M. V., Samoilova, O. S., Davydkin, I. L., Алексеевич, Г. Т., Kaplanov, K. D., Kaporskaya, T. S., Shelekhova, T. V., Volodicheva, E. M., et al. (2026) · Гематология и трансфузиология · doi:10.35754/0234-5730-2026-71-2-142-160
Evolution of real-world frontline treatment patterns in multiple myeloma
Lazzaro, A., Nannini, K., Yildirim, C., Huhmann, L., Culnan, J., Corrigan, J. K., Elbers, D. C., Do, N., Brophy, M. T., Munshi, N. C., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019843
Kikuchi, J., & Yasui, H. (2026) · Cells · doi:10.3390/cells15151331
“In particular, amplification of the chromosome 1q21 region (1q gain), the most common cytogenetic abnormality in MM [2], has recently emerged as a potential determinant of differential sensitivity to anti-CD38 antibodies [3,4].”
Kecman, N., Sretenovic, A., Mitrovic, M., Bukumirić, Z., Tanović, I., Vukosavljevic, N., Jovanović, J., Fekete, M. D., & Bila, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1869023
Revolutionizing 2L+ Myeloma: A Podcast on the New Era of BCMA-Targeted Bispecific Antibody Therapies
Mina, R., Doyle, M., & Nooka, A. K. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03715-z
Qi, J., Park, D., Shah, P., & Akhtari, M. (2026) · Hematology Reports · doi:10.3390/hematolrep18040054
“Standard frontline therapy for newly diagnosed MM typically includes combinations of immunomodulatory agents, proteasome inhibitors, and corticosteroids, with the addition of anti-CD38 monoclonal antibodies further improving clinical outcomes [4,5].”
Akrawi, D., Datta, S., Hatipoğlu, S., Wechalekar, A. D., Ghose, A., Alkhateeb, A., Walker, J. M., & Ghosh, A. K. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02397-x
“…in MM have improved dramatically: with front-line isatuximab–bortezomib–lenalidomide–dexamethasone (Isa-VRd), an estimated 63% of newly diagnosed patients remain progression-free at five years, and extrapolation of these data projects a median progression-free survival of up to 17 years [ 77].”
Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies
Mathias, F., Fersing, C., Bourgarel‐Rey, V., Gabert, J. A., & Peyron, F. (2026) · Cells · doi:10.3390/cells15161439
“This trial demonstrated https://doi.org/10.3390/cells15161439 significantly higher estimated 60-month PFS (63.2% vs. 45.2%; p < 0.001) and complete response rates (74.7% vs. 64.1%; p = 0.01) in the isatuximab-VRd group compared with the VRd group [38].”
InfluentialMultiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70475 · Cited by 5
Facon, T. T. F., Kumar, S. K., Orlowski, R. Z., Bahlis, N. J., Moreau, P., Goldschmidt, H., Basu, S., Hulin, C., Zweegman, S., Weisel, K. C., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03097-9
Self-citationKato, Y., Suzuki, T., Kondo, A., Matsunaga, N., Kikuchi, T., Kanamori, T., Yoshida, T., Kayukawa, S., Asao, Y., Yano, H., et al. (2026) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2026.103096
EXABS-198-MM: Frailty in Multiple Myeloma: Implications Across the Treatment Landscape
Mian, H. S. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(26)00327-7
Yu, L., Li, C., Guo, D., & Cui, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1932951
IFM 2026 Recommendations for First-line Treatment of Newly Diagnosed Multiple Myeloma
Perrot, A., Manier, S., Hulin, C., Demarquette, H., Bobin, A., Frenzel, L., Karlin, L., Decaux, O., Mohty, M., Arnulf, B., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.002
Self-citationTreatment Decisions in Multiple Myeloma
Mouhieddine, T. H., & Anderson, K. C. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2605253 · Cited by 1
Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making
Bazarbachi, A. H., Lentzsch, S., Facon, T. T. F., Harousseau, J., & Mohty, M. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00545
Self-citationBlair, P., Chu, T., Robinson, A., Saja, K., Rushworth, S. A., Zwacka, R. M., & Mohr, A. (2026) · Cytokine · doi:10.1016/j.cyto.2026.157213
Zhu, F., & Wang, H. (2026) · Cancer Medicine · doi:10.1002/cam4.72270
Gu, L. C., Raval, O., Ji, X. (., Joseph, N., Hofmeister, C. C., Gupta, V. A., Parikh, R., Shah, N., Mina, R., Switchenko, J. M., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.013
Minimal Residual Disease (MRD) in Multiple Myeloma: From Prognostic Marker to Therapeutic Compass
Tamariz‐Amador, L., Rodríguez‐Otero, P., Manubens, A., Lasa, M., Gonzalez, C., Paiva, B., & San-Miguel, J. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000846
Joshi, A., Puliafito, B. R., Cirstea, D. D., Branagan, A. R., Gustine, J. N., Shome, R., Panaroni, C., Yee, A. J., & Raje, N. S. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000853
Proteostasis as a Therapeutic Backbone: Proteasome Inhibitors and Emerging Regimens
Song, Y., Theprungsirikul, P., Gullà, A., & Anderson, K. C. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000852
Usmani, S. Z., Facon, T. T. F., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M. J., Pour, L., Martí, J. M., Basu, S., Cohen, Y. C., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00401
Self-citationNtanasis‐Stathopoulos, I., Terpos, E., & Dimopoulos, M. A. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000845
Self-citationTailoring Therapy for Frail and Elderly Myeloma Patients
George, T., & Szalat, R. E. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000850
Younis, O. M., Göklemez, S., Awadallah, C., Atrash, S., Paul, B. A., Shaikh, H. G., Strouse, C. S., Vegel, A. J., Struble, E., Mazloom, A., et al. (2026) · Cancers · doi:10.3390/cancers18193147
Corre, J., Lambert, J., Bobin, A., Manier, S., Perrot, A., Karlin, L., Roussel, M., Bigot, N., Benbrahim, O., Allangba, O. T., et al. (2026) · HemaSphere · doi:10.1002/hem3.70482
“1,2 Patients with HRMM encompass a heterogeneous group involving various definitions and a common experience of shorter survival times, as they benefit to a lesser extent from discoveries of drugs and regimens in terms of treatment.”
InfluentialSelf-citationBobin, A., Durocher, L., Touzeau, C., Branche, N., Perrot, A., Dib, M., Blade, J., Chalopin, T., Montes, L., Gay, J., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01634-4
Self-citationTerlizzi, S., Falcone, T., Frittoli, B., Ribolla, R., Crippa, C., Ferrari, S., Bianchetti, N., Bottelli, C., Vietti, E., Avenoso, D., et al. (2026) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2026.104640
Tsukamoto, T., Shimura, Y., Mizutani, S., Fujino, T., Okamoto, H., Itagaki, M., Handa, H., Shimizu, T., Sawamura, M., Ishida, T., et al. (2026) · Cancer Science · doi:10.1111/cas.70564
Self-citationAly, A. S., Elmestiri, M., Yacoub, J., Yacoub, Z., Abulbida, S., & Idris, A. E. (2026) · Research Square · doi:10.21203/rs.3.rs-11431265/v1
Metadata
- Authors
- Facon, T., Dimopoulos, M.-A., Leleu, X. P., Beksac, M., Pour, L., Hájek, R., Liu, Z., Minarik, J., Moreau, P., Romejko-Jarosinska, J., Spicka, I., Vorobyev, V. I., Besemer, B., Ishida, T., Janowski, W., Kalayoglu-Besisik, S., Parmar, G., Robak, P., Zamagni, E., Goldschmidt, H., Martin, T. G., Manier, S., Mohty, M., Oprea, C., Brégeault, M.-F., Macé, S., Berthou, C., Bregman, D., Klippel, Z., & Orlowski, R. Z.
- Affiliations
- Inserm (FR)
- From the Department of Hematology, Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Lille (T.F., S. Manier), the French National Academy of Medicine (T.F.), and the Department of Hematology, Hôpital Saint-Antoine, Sorbonne University and INSERM (M.M.), Paris, Service d’Hématologie et Thérapie Cellulaire, CHU and Centre d’Investigation Clinique INSERM Unité 1402, Poitiers (X.P.L.), the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.), and Sanofi, Research and Development, Vitry-sur-Seine (C.O., M.-F.B., S. Macé, C.B.) — all in France; the Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens (M.-A.D.); the Department of Hematology, Ankara University, and the Istinye University Ankara Liv Hospital, Ankara (M.B.), and the Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul (S.K.-B.) — all in Turkey; the Department of Internal Medicine, Hematology, and Oncology, Uni...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-31
- Volume
- 391
- Issue
- 17
- Pages
- 1597-1609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399304831
- Semantic Scholar
- a45e6cd60318735bf0f85aba849da20117440058
- Cited by
- 284
- References
- 30
- Citations by year
- 2026: 100 · 2025: 155 · 2024: 29
- FWCI
- 87.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- isatuximab, bortezomib, lenalidomide, dexamethasone, multiple myeloma, newly diagnosed multiple myeloma, anti-CD38 monoclonal antibody, progression-free survival, complete response, minimal residual disease, transplant-ineligible patients, first-line therapy
- MeSH terms
- Bortezomib, Lenalidomide, Progression-Free Survival, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm, Residual, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.